288 related articles for article (PubMed ID: 27060463)
61. Tenascin-C in primary malignant melanoma of the skin.
Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S
Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480
[TBL] [Abstract][Full Text] [Related]
62. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
63. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
64. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
65. Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.
Espíndola MB; Corleta OC
World J Surg Oncol; 2008 Jun; 6():65. PubMed ID: 18570663
[TBL] [Abstract][Full Text] [Related]
66. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
67. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
[TBL] [Abstract][Full Text] [Related]
68. Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.
Nájera L; Alonso-Juarranz M; Garrido M; Ballestín C; Moya L; Martínez-Díaz M; Carrillo R; Juarranz A; Rojo F; Cuezva JM; Rodríguez-Peralto JL
Br J Dermatol; 2019 Jul; 181(1):114-127. PubMed ID: 30537064
[TBL] [Abstract][Full Text] [Related]
69. Maspin expression in the invasive margin of primary melanomas may reflect an aggressive tumor phenotype.
Pföhler C; Knöpflen T; Körner R; Vogt T; Rösch A; Müller CS
J Dtsch Dermatol Ges; 2013 Oct; 11(10):993-9. PubMed ID: 23848940
[TBL] [Abstract][Full Text] [Related]
70. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.
Saldanha G; Joshi K; Lawes K; Bamford M; Moosa F; Teo KW; Pringle JH
Mod Pathol; 2017 Jan; 30(1):60-68. PubMed ID: 27713424
[TBL] [Abstract][Full Text] [Related]
71. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
72. Tumor stem cells (CD271, c-kit, SOX10) in Melanomas: prognostic and outcome implications.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2014; 22(2):142-5. PubMed ID: 23958542
[TBL] [Abstract][Full Text] [Related]
73. Overexpression of adenylate cyclase-associated protein 2 is a novel prognostic marker in malignant melanoma.
Masugi Y; Tanese K; Emoto K; Yamazaki K; Effendi K; Funakoshi T; Mori M; Sakamoto M
Pathol Int; 2015 Dec; 65(12):627-34. PubMed ID: 26374196
[TBL] [Abstract][Full Text] [Related]
74. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique.
Rutkowski P; Szydłowski K; Nowecki ZI; Sałamacha M; Goryń T; Mitręga-Korab B; Pieńkowski A; Dziewirski W; Zdzienicki M
World J Surg Oncol; 2015 Oct; 13():299. PubMed ID: 26462471
[TBL] [Abstract][Full Text] [Related]
75. Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma.
Shimizu A; Kaira K; Yasuda M; Asao T; Ishikawa O
Neoplasma; 2016; 63(2):282-7. PubMed ID: 26774151
[TBL] [Abstract][Full Text] [Related]
76. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma.
Bron LP; Scolyer RA; Thompson JF; Hersey P
Pathology; 2004 Dec; 36(6):561-5. PubMed ID: 15841691
[TBL] [Abstract][Full Text] [Related]
77. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
78. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
79. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
80. GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.
Hu H; Li Z; Zhou Y; Zhang Y; Zhao L; Zhao W; Huang Y; Song X
Melanoma Res; 2019 Dec; 29(6):612-620. PubMed ID: 31305325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
